Gross Profit Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Vericel Corporation

Biotech Giants: Alnylam vs. Vericel's Profit Journey

__timestampAlnylam Pharmaceuticals, Inc.Vericel Corporation
Wednesday, January 1, 20145056100011503000
Thursday, January 1, 20154109700024698000
Friday, January 1, 20164715900026076000
Sunday, January 1, 20177654500033570000
Monday, January 1, 20187310600058697000
Tuesday, January 1, 201919468800080279000
Wednesday, January 1, 202041480100084228000
Friday, January 1, 2021704143000106025000
Saturday, January 1, 2022868601000109788000
Sunday, January 1, 20231517886000135576000
Monday, January 1, 20241924873000
Loading chart...

Unleashing the power of data

A Tale of Two Biotechs: Alnylam vs. Vericel

In the dynamic world of biotechnology, Alnylam Pharmaceuticals, Inc. and Vericel Corporation have carved distinct paths over the past decade. From 2014 to 2023, Alnylam's gross profit surged by an impressive 2,900%, reflecting its robust growth and strategic advancements in RNA interference therapeutics. In contrast, Vericel, specializing in advanced cell therapies, experienced a more modest yet steady increase of approximately 1,080% in the same period.

Key Insights

  • Alnylam's Growth: By 2023, Alnylam's gross profit reached a staggering 1.52 billion, a testament to its innovative pipeline and market expansion.
  • Vericel's Steady Climb: Vericel's gross profit, while smaller, grew consistently, peaking at 136 million in 2023.

This comparison highlights the diverse strategies and market dynamics within the biotech sector, offering valuable insights for investors and industry enthusiasts alike.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025